Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
1.
Microb Drug Resist ; 27(9): 1167-1175, 2021 Sep.
Article in English | MEDLINE | ID: mdl-33600262

ABSTRACT

Background: The aim of this study was to assess the drivers of multidrug-resistant (MDR) bacterial infection development in coronavirus disease 2019 (COVID-19) and its impact on patient outcome. Methods: Retrospective analysis on data from 32 consecutive patients with COVID-19, admitted to our intensive care unit (ICU) from March to May 2020. Outcomes considered were MDR infection and ICU mortality. Results: Fifty percent of patients developed an MDR infection during ICU stay after a median time of 8 [4-11] days. Most common MDR pathogens were carbapenem-resistant Klebsiella pneumoniae and Acinetobacter baumannii, causing bloodstream infections and pneumonia. MDR infections were linked to a higher length of ICU stay (p = 0.002), steroid therapy (p = 0.011), and associated with a lower ICU mortality (odds ratio: 0.439, 95% confidence interval: 0.251-0.763; p < 0.001). Low-dose aspirin intake was associated with both MDR infection (p = 0.043) and survival (p = 0.015). Among MDR patients, mortality was related with piperacillin-tazobactam use (p = 0.035) and an earlier onset of MDR infection (p = 0.042). Conclusions: MDR infections were a common complication in critically ill COVID-19 patients at our center. MDR risk was higher among those dwelling longer in the ICU and receiving steroids. However, MDR infections were not associated with a worse outcome.


Subject(s)
Acinetobacter Infections/mortality , COVID-19/mortality , Drug Resistance, Multiple, Bacterial , Klebsiella Infections/mortality , Opportunistic Infections/mortality , Pneumonia/mortality , SARS-CoV-2/pathogenicity , Acinetobacter Infections/drug therapy , Acinetobacter Infections/microbiology , Acinetobacter Infections/virology , Acinetobacter baumannii/drug effects , Acinetobacter baumannii/growth & development , Acinetobacter baumannii/pathogenicity , Adult , Aged , Anti-Bacterial Agents/therapeutic use , Aspirin/therapeutic use , COVID-19/microbiology , COVID-19/virology , Carbapenems/therapeutic use , Critical Illness , Female , Hospital Mortality , Humans , Intensive Care Units , Klebsiella Infections/drug therapy , Klebsiella Infections/microbiology , Klebsiella Infections/virology , Klebsiella pneumoniae/drug effects , Klebsiella pneumoniae/growth & development , Klebsiella pneumoniae/pathogenicity , Length of Stay/statistics & numerical data , Male , Middle Aged , Opportunistic Infections/drug therapy , Opportunistic Infections/microbiology , Opportunistic Infections/virology , Piperacillin, Tazobactam Drug Combination/therapeutic use , Pneumonia/drug therapy , Pneumonia/microbiology , Pneumonia/virology , Retrospective Studies , SARS-CoV-2/drug effects , SARS-CoV-2/physiology , Steroids/therapeutic use , Survival Analysis , Treatment Outcome , COVID-19 Drug Treatment
2.
J Glob Antimicrob Resist ; 23: 398-400, 2020 12.
Article in English | MEDLINE | ID: mdl-33242674

ABSTRACT

Here we report on seven intensive care unit (ICU) patients with coronavirus disease 2019 (COVID-19)-related acute respiratory distress syndrome (ARDS) who developed positive rectal swabs and invasive infections due to carbapenemase-producing Klebsiella pneumoniae (CP-Kp). Notwithstanding the infection prevention measures introduced during the COVID-19 pandemic and changes in the hospitalised population, attention to CP-Kp infections must remain high, especially in the critically ill setting.


Subject(s)
COVID-19/microbiology , Carbapenem-Resistant Enterobacteriaceae/isolation & purification , Klebsiella Infections/virology , Klebsiella pneumoniae/isolation & purification , Adult , Aged , COVID-19/diagnosis , COVID-19/epidemiology , COVID-19/therapy , Coinfection/epidemiology , Critical Illness , Female , Humans , Intensive Care Units/statistics & numerical data , Italy/epidemiology , Klebsiella Infections/epidemiology , Klebsiella Infections/microbiology , Klebsiella Infections/therapy , Male , Middle Aged , SARS-CoV-2/isolation & purification
3.
Article in English | MEDLINE | ID: mdl-31907184

ABSTRACT

Oral fosfomycin trometamol is licensed as a single oral dose for the treatment of uncomplicated urinary tract infections, with activity against multidrug-resistant uropathogens. The impact of interindividual variability in urinary concentrations on antimicrobial efficacy, and any benefit of giving multiple doses, is uncertain. We therefore performed pharmacodynamic profiling of oral fosfomycin, using a dynamic bladder infection in vitro model, to assess high and low urinary exposures following a single oral dose and three repeat doses given every 72 h, 48 h, and 24 h against 16 clinical isolates with various MICs of fosfomycin (8 Escherichia coli, 4 Enterobacter cloacae, and 4 Klebsiella pneumoniae isolates). Baseline fosfomycin high-level-resistant (HLR) subpopulations were detected prior to drug exposure in half of the isolates (2 E. coli, 2 E. cloacae, and 4 K. pneumoniae isolates; proportion, 1 × 10-5 to 5 × 10-4% of the total population). Fosfomycin exposures were accurately reproduced compared to mathematical modeling (linear regression slope, 1.1; R2, 0.99), with a bias of 3.8% ± 5.7%. All 5/5 isolates with MICs of ≤1 µg/ml had no HLR and were killed, whereas 8/11 isolates with higher MICs regrew regardless of exposure to high or low urinary concentrations. A disk diffusion zone of <24 mm was a better predictor for baseline HLR and regrowth. Administering 3 doses with average exposures provided very limited additional kill. These results suggest that baseline heteroresistance is important for treatment response, while increased drug exposure and administering multiple doses may not be better than standard single-dose fosfomycin therapy.


Subject(s)
Anti-Bacterial Agents/administration & dosage , Anti-Bacterial Agents/therapeutic use , Escherichia coli/drug effects , Escherichia coli/metabolism , Fosfomycin/administration & dosage , Fosfomycin/therapeutic use , Urinary Tract Infections/drug therapy , Urinary Tract Infections/virology , Escherichia coli/pathogenicity , Escherichia coli Infections/drug therapy , Escherichia coli Infections/virology , Humans , Klebsiella Infections/drug therapy , Klebsiella Infections/virology , Klebsiella pneumoniae/drug effects , Klebsiella pneumoniae/metabolism , Klebsiella pneumoniae/pathogenicity , Microbial Sensitivity Tests
5.
Sci Rep ; 7(1): 17291, 2017 12 11.
Article in English | MEDLINE | ID: mdl-29230010

ABSTRACT

In the study, 15 K. pneumoniae strains were isolated from the mink experiencing respiratory distress in mideastern Shandong province, China, and the prevalence of K. pneumoniae in the sampled mink was 11.9% (15/126). Fourteen (93.33%) of the 15 K. pneumoniae isolates were identified as serotype K2 and hypermucoviscosity phenotype. The 12 virulence-associated genes of the K. pneumoniae isolates were tested. The prevalence of the wabG gene for the isolates were 100% (15/15), the ureA gene 100% (15/15), the rmpA gene 93.33% (14/15), the aerobactin gene 93.33% (14/15), the uge gene 93.33% (14/15), the IucB gene 80% (12/15) and the ybtA gene 13.33% (2/15). But the other five genes, fim, iroNB, wcaG, alls and kfuBC, gave a negative PCR reaction in the 15 isolates, respectively. The animal experiments using K. pneumoniae-SD-12 and K. pneumoniae-SD-21 demonstrated that the serotype K2 was high virulence for mice and mink. These finding implied there exist potential threat that K. pneumoniae pathogens could transmit to human, especially the fur animal farm workers and residents lived near the fur animal farms. Therefore, the etiology and epidemiological surveillance of K. pneumoniae in mink should be strengthened for people's public health.


Subject(s)
Bacterial Proteins/metabolism , Klebsiella Infections/epidemiology , Klebsiella pneumoniae/pathogenicity , Liver Abscess/epidemiology , Respiration Disorders/epidemiology , Serogroup , Virulence Factors/metabolism , Animals , Bacterial Proteins/genetics , China/epidemiology , Incidence , Klebsiella Infections/genetics , Klebsiella Infections/virology , Liver Abscess/genetics , Liver Abscess/virology , Mice , Mink , Phenotype , Respiration Disorders/genetics , Respiration Disorders/virology , Virulence Factors/genetics
6.
J Microbiol Biotechnol ; 19(6): 622-8, 2009 Jun.
Article in English | MEDLINE | ID: mdl-19597322

ABSTRACT

In the present study, the therapeutic potential of purified and well-characterized bacteriophages was evaluated in thermally injured mice infected with Klebsiella pneumoniae B5055. The efficacy of five Klebsiella phages (Kpn5, Kpn12, Kpn13, Kpn17, and Kpn22) was evaluated on the basis of survival rate, decrease in bacterial counts in different organs of phage-treated animals, and regeneration of skin cells as observed by histopathological examination of phage-treated skin. Toxicity studies performed with all the phages showed them to be non-toxic, as no signs of morbidity and mortality were observed in phage-treated mice. The results of the study indicate that a single dose of phages, intraperitoneally (i.p.) at an MOI of 1.0, resulted in significant decrease in mortality, and this dose was found to be sufficient to completely cure K. pneumoniae infection in the burn wound model. Maximum decrease in bacterial counts in different organs was observed at 72 h post infection. Histopathological examination of skin of phage-treated mice showed complete recovery of burn infection. Kpn5 phage was found to be highly effective among all the phages and equally effective when compared with a cocktail of all the phages. From these results, it can be concluded that phase therapy may have the potential to be used as stand-alone therapy for K.pneumoniae induces burn wound infection, especially in situations where multiple antibiotic-resistant organisms are encountered.


Subject(s)
Bacteriophages/metabolism , Biological Therapy/methods , Burns/microbiology , Klebsiella Infections/virology , Klebsiella pneumoniae/virology , Wound Infection/therapy , Animals , Bacteriophages/isolation & purification , Biological Therapy/adverse effects , Burns/pathology , Burns/therapy , Colony Count, Microbial , Klebsiella Infections/metabolism , Klebsiella pneumoniae/metabolism , Mice , Mice, Inbred BALB C , Skin/pathology , Time Factors , Treatment Outcome , Wound Infection/microbiology , Wound Infection/pathology
7.
Diagn Microbiol Infect Dis ; 62(1): 1-6, 2008 Sep.
Article in English | MEDLINE | ID: mdl-18486404

ABSTRACT

Hypermucoviscosity, rmpA (regulator of mucoid phenotype), aerobactin (an iron siderophore), kfu (an iron uptake system), allS (associated with allantoin metabolism), and K1/K2 capsules are important virulence determinants in Klebsiella pneumoniae for liver abscesses. We determined the prevalence of these virulence factors of 50 nonrepeat K. pneumoniae isolates recovered from patients with primary liver abscesses who were treated at 2 medical centers in Taiwan. Virulence genes were surveyed by polymerase chain reaction analysis. The prevalence of hypermucoviscosity phenotype, plasmid-born rmpA, aerobactin, kfu, and allS genes revealed 96%, 100%, 100%, 100%, and 100% in 26 capsular K1 isolates; 90%, 100%, 100%, 0%, and 0% in 10 K2 isolates; and 79%, 86%, 93%, 50%, and 0% in 14 non-K1/K2 isolates; respectively. When injected into mice intraperitoneally, regardless of any capsule K serotype, K. pneumoniae isolates with hypermucoviscosity phenotype as well as presence of rmpA and aerobactin genes exhibited high virulence for mouse lethality (LD(50), <10(2) CFU). Without significant difference in the prevalence of expressing hypermucoviscosity phenotype and carriage of rmpA and aerobactin genes, these virulent non-K1/K2 isolates are as capable as K1/K2 isolates of causing primary liver abscesses.


Subject(s)
Bacterial Capsules , Klebsiella pneumoniae/classification , Klebsiella pneumoniae/pathogenicity , Liver Abscess , Virulence Factors/metabolism , Animals , Antigens, Bacterial , Bacterial Proteins/genetics , Bacterial Proteins/metabolism , Humans , Hydroxamic Acids/metabolism , Klebsiella Infections/epidemiology , Klebsiella Infections/virology , Klebsiella pneumoniae/isolation & purification , Klebsiella pneumoniae/physiology , Liver Abscess/epidemiology , Liver Abscess/virology , Mice , Phenotype , Polysaccharides, Bacterial , Prevalence , Serotyping , Taiwan/epidemiology , Virulence , Virulence Factors/genetics , Viscosity
8.
Int J Gynecol Pathol ; 27(2): 282-7, 2008 Apr.
Article in English | MEDLINE | ID: mdl-18317211

ABSTRACT

We describe concomitant granuloma inguinale (GI) and malacoplakia of the cervix in 2 acquired immune deficiency syndrome (AIDS) patients aged 27 and 36 years. Both patients presented with a bloody foul-smelling vaginal discharge. Speculum examination confirmed cervical ulceration, prompting the diagnosis of cervical carcinoma in both patients. Cervical punch biopsies confirmed the characteristic features of GI; granulation tissue containing a dense plasma cell infiltrate, aggregates of neutrophils, and vacuolated enlarged histiocytes containing Donovan bodies were noted. Many of these histiocytes and sheets of von Hansemann cells contained intracytoplasmic Michaelis-Gutmann bodies, confirming concomitant malacoplakia. Michaelis-Gutmann bodies were also present in extracellular locations. Ultrastructural examination confirmed these histopathologic findings. One patient died of disseminated tuberculosis before treatment was initiated. The other patient did not return for a follow-up visit of her cervical lesion. Concomitant GI and malacoplakia is unreported in genital and extragenital sites; Klebsiella granulomatis must therefore be added to the list of bacteria associated with malacoplakia. Malacoplakia of the female genital tract is documented rarely and remains unreported, to date, in AIDS patients. Similar to the pathogenetic mechanisms described for AIDS-associated malacoplakia in extragenital sites, it is hypothesized that, in addition to abnormal macrophage functioning and an inability to degrade bacteria, special constituents of K. granulomatis are undigestable by lysosomal enzymes in human immunodeficiency virus-infected patients.


Subject(s)
AIDS-Related Opportunistic Infections/virology , Acquired Immunodeficiency Syndrome/complications , Granuloma Inguinale/virology , Klebsiella Infections/virology , Malacoplakia/virology , Uterine Cervical Diseases/virology , AIDS-Related Opportunistic Infections/diagnosis , Adult , Biopsy , Cervix Uteri/microbiology , Cervix Uteri/pathology , Female , Granuloma Inguinale/diagnosis , Humans , Klebsiella Infections/diagnosis , Malacoplakia/diagnosis , Uterine Cervical Diseases/diagnosis
9.
Emerg Radiol ; 13(2): 87-8, 2006 Nov.
Article in English | MEDLINE | ID: mdl-16951940

ABSTRACT

Patients with pyogenic liver abscesses often present to the emergency department with fever of unknown origin. After the appropriate clinical evaluation, cross-sectional imaging may be performed in the emergent setting to aid in localization of fever source. On computed tomography imaging, pyogenic liver abscesses may present as inflammatory masses in the liver, with Escherichia coli as the most common pathogen. We report an emerging hepatic pathogen as the cause, Klebsiella pneumoniae.


Subject(s)
Klebsiella Infections/complications , Klebsiella pneumoniae , Liver Abscess, Pyogenic/microbiology , Aged , Anti-Bacterial Agents/therapeutic use , Cefepime , Cephalosporins/therapeutic use , Humans , Klebsiella Infections/diagnostic imaging , Klebsiella Infections/drug therapy , Klebsiella Infections/virology , Liver Abscess, Pyogenic/diagnostic imaging , Liver Abscess, Pyogenic/drug therapy , Male , Tomography, X-Ray Computed
SELECTION OF CITATIONS
SEARCH DETAIL
...